Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib versus gefitinib + bevacizumab in EGFR L858R-mutant advanced non-small cell lung cancer
ChiCTR2000032720Phase 4Not yet recruiting
- Sponsor
- Ya'an People's Hospital
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gefitinib and bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Ya'an People's Hospital. Primary endpoints: Progression-free survival and Adverse reactions. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
gefitinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000032720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032720.